The Zhitong Finance App learned that Gilead Sciences (GILD.US) rose nearly 9% to $120.07 on Friday. Financial reports show that in the second quarter of 2025, Gilead Scientific's revenue increased 2% to US$7.08 billion, exceeding market expectations of US$6.98 billion; adjusted earnings per share were US$2.01, higher than market expectations of US$1.96. CEO Daniel O'Day said growth was driven by Biktarvy, Descovy, Trodelvy, and Livdelzi.

Zhitongcaijing · 08/08/2025 14:49
The Zhitong Finance App learned that Gilead Sciences (GILD.US) rose nearly 9% to $120.07 on Friday. Financial reports show that in the second quarter of 2025, Gilead Scientific's revenue increased 2% to US$7.08 billion, exceeding market expectations of US$6.98 billion; adjusted earnings per share were US$2.01, higher than market expectations of US$1.96. CEO Daniel O'Day said growth was driven by Biktarvy, Descovy, Trodelvy, and Livdelzi.